1-(2,3-Dichlorophenyl)piperazine Hydrochloride CAS 119532-26-2 Aripiprazole Intermediate Purity>99.0% (HPLC)
AbaPhakathi boBonelelo boMvelisi be-Aripiprazole Ngobunyulu obuPhezulu
Aripiprazole API CAS 129722-12-9
1-(2,3-Dichlorophenyl)piperazine Hydrochloride CAS 119532-26-2
I-7-Hydroxy-3,4-Dihydro-2 (1H)-Quinolinone CAS 22246-18-0
7-(4-Bromobutoxy)-3,4-Dihydro-2(1H)-Quinolinone CAS 129722-34-5
Igama leMchiza | 1-(2,3-Dichlorophenyl) piperazine Hydrochloride |
Izithethantonye | 2,3-DCPP HCl;I-1-(2,3-Dichlorophenyl) piperazine HCl;I-Aripiprazole EP Ukungcola B;I-Aripiprazole eNxulumene nayo iCompound C |
Inombolo yeCAS | 119532-26-2 |
Inombolo yeCAT | RF-PI2268 |
Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ye-30 MT / inyanga |
Ifomula yeemolekyuli | C10H12Cl2N2·HCl |
Ubunzima beMolekyuli | 267.58 |
Indawo yokunyibilika | 245.0 ~ 247.0℃ |
Ugcino & Novakalelo | Hygroscopic.Amaqondo obushushu e-Ambient |
Ukunyibilika emanzini | Inyibilika emanzini |
Uphawu | Ruifu Chemical |
Into | Iinkcukacha |
Imbonakalo | Umgubo oMhlophe okanye oMhlophe |
Ubunyulu / Indlela yokuHlalutya | >99.0% (HPLC) |
Ilahleko ekomisweni | <0.50% |
Intsalela kwi-Ignition | <0.10% |
Ukungacoceki Okukodwa | <0.50% |
Ukungcola ngokupheleleyo | <1.00% |
Iintsimbi ezinzima (njenge Pb) | ≤20ppm |
I-Infrared Spectrum | Iyahambelana neSakhiwo |
Umgangatho woVavanyo | Umgangatho woShishino |
Ukusetyenziswa | Umbindi we-Aripiprazole (CAS: 129722-12-9) |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi
Imeko yoGcino:Hygroscopic.Gcina kude namanzi / ukufuma kunye nee-oxidizing agents.Gcina isikhongozeli sivalwe ngokuqinileyo kwaye usibeke kwindawo epholileyo, eyomileyo kwaye engenamoya.Gcina phantsi kwegesi engasebenziyo
I-1-(2,3-Dichlorophenyl) i-piperazine Hydrochloride (CAS: 119532-26-2) yinto ebalulekileyo ephakathi kwe-Aripiprazole (CAS: 129722-12-9).I-Aripiprazole luhlobo olutsha lwezinto eziphuma kwi-quinoline ezine-lipid enyibilikayo, iimpawu zayo ze-pharmacological kukuba ayisiyiyo kuphela i-postsynaptic dopamine D 2 receptor antagonist, kodwa kunye ne-presynaptic dopamine D 2 receptor agonist, inokuvuyisa i-D 1, D 3, D 4 i-receptors;ineempembelelo ezimbini zokusebenzisa inxalenye okanye i-receptor antagonistic kwi-5-HT 1A i-receptor;inesenzo esichasayo ngokupheleleyo kwi-5-HT 2A receptor.Olu phawu lwahlukile kwisizukulwana sokuqala, kunye ne-atypical antipsychotics eyeyesibini isizukulwana sesibini seziyobisi, kwaye ke ibizwa ngokuba yi-dopamine system stabilizer okanye i-antipsychotic yesizukulwana sesithathu.Ekubeni ithengiswa kwimarike, isetyenziswa ikakhulu kwi-schizophrenia yeklinikhi, unyango lweengxaki ezichaphazelekayo kunye nezinye izifo zengqondo.Ngokutsho kweencwadi, i-aripiprazole ineempembelelo ezibalulekileyo kwi-schizophrenia iimpawu ezintle kunye ezimbi kunye nokuxhalaba, ukudakumba, umsebenzi wokuqonda, ngelixa ukhuseleko oluphezulu.Kwakhona kwaxelwa ukuba ichiza nako ukunyanga ezinye ukuphazamiseka kwengqondo, ezifana ukuphazamiseka kweemvakalelo manic episodes, senile dementia ezinxulumene nokuphazamiseka kwengqondo, ukuphazamiseka ixhala, ukuphazamiseka ukuziphatha abantwana, ukudakumba.Ngoku, iBristol-Myers Squibb kunye ne-Otsuka Pharmaceutical Company yabhengeza ukuba i-European Union yamnkele i-Abilify (aripiprazole) kunyango lwesicelo soluhlu lwe-schizophrenia.